Baptist Hospital
Global Vaccine Adjuvants Market To Reach $1.5 Billion By 2030
ReportLinkerThe global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, April 17, 2023 (GLOBE NEWSWIRE) -- Reportlinker.Com announces the release of the report "Global Vaccine Adjuvants Industry" - https://www.Reportlinker.Com/p06043964/?Utm_source=GNWFood and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Vaccine Adjuvants Market to Reach $1.5 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Vaccine Adjuvants estimated at US$735.7 Million in the year 2022, is projected to reach a revised size of US$1.5 Billion by 2030, growing at aCAGR of 9.1% over the period 2022-2030. Particulate Adjuvants, one of the segments analyzed in the report, is projected to record 8.6% CAGR and reach US$513.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Adjuvant Emulsions segment is readjusted to a revised 8.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $218.7 Million, While China is Forecast to Grow at 8.4% CAGR
The Vaccine Adjuvants market in the U.S. Is estimated at US$218.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$252.5 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8% and 7.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.
Select Competitors (Total 44 Featured)- Agenus, Inc.- Avanti Polar Lipids, Inc.- Brenntag Biosector A/S- CSL Ltd.- Invivogen- Mvp Laboratories Inc.- Novavax, Inc.- OZ Biosciences SAS- Seppic SA- SPI Pharma
Read the full report: https://www.Reportlinker.Com/p06043964/?Utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEWInfluencer Market InsightsWorld Market TrajectoriesVaccine Adjuvants - Global Key Competitors Percentage MarketShare in 2021 (E)Competitive Market Presence - Strong/Active/Niche/Trivial forPlayers Worldwide in 2021 (E)Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVETable 1: World Recent Past, Current & Future Analysis forVaccine Adjuvants by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2022 through 2030 and % CAGR
Table 2: World Historic Review for Vaccine Adjuvants byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 3: World 16-Year Perspective for Vaccine Adjuvants byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld Markets for Years 2014, 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis forParticulate Adjuvants by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2022 through 2030 and % CAGR
Table 5: World Historic Review for Particulate Adjuvants byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 6: World 16-Year Perspective for Particulate Adjuvants byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis forAdjuvant Emulsions by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2022 through 2030 and % CAGR
Table 8: World Historic Review for Adjuvant Emulsions byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 9: World 16-Year Perspective for Adjuvant Emulsions byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis forPathogen Components by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2022 through 2030 and % CAGR
Table 11: World Historic Review for Pathogen Components byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 12: World 16-Year Perspective for Pathogen Components byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 13: World Recent Past, Current & Future Analysis forCombination Adjuvants by Geographic Region - USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2022 through 2030 and % CAGR
Table 14: World Historic Review for Combination Adjuvants byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 15: World 16-Year Perspective for Combination Adjuvantsby Geographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 16: World Recent Past, Current & Future Analysis forOther Types by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2022 through2030 and % CAGR
Table 17: World Historic Review for Other Types by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific andRest of World Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2014 through 2021 and % CAGR
Table 18: World 16-Year Perspective for Other Types byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 19: World Recent Past, Current & Future Analysis forInfectious Diseases by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2022 through 2030 and % CAGR
Table 20: World Historic Review for Infectious Diseases byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 21: World 16-Year Perspective for Infectious Diseases byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 22: World Recent Past, Current & Future Analysis forCancer by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2022 through2030 and % CAGR
Table 23: World Historic Review for Cancer by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 24: World 16-Year Perspective for Cancer by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World for Years2014, 2023 & 2030
Table 25: World Recent Past, Current & Future Analysis forOther Disease Types by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2022 through 2030 and % CAGR
Table 26: World Historic Review for Other Disease Types byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 27: World 16-Year Perspective for Other Disease Types byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 28: World Recent Past, Current & Future Analysis forHuman by Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2022 through 2030 and% CAGR
Table 29: World Historic Review for Human by Geographic Region -USA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 30: World 16-Year Perspective for Human by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World for Years2014, 2023 & 2030
Table 31: World Recent Past, Current & Future Analysis forVeterinary by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2022 through2030 and % CAGR
Table 32: World Historic Review for Veterinary by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific andRest of World Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2014 through 2021 and % CAGR
Table 33: World 16-Year Perspective for Veterinary byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2014, 2023 & 2030
Table 34: World Vaccine Adjuvants Market Analysis of AnnualSales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATESVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in the United States for 2023 (E)Table 35: USA Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 36: USA Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components,Combination Adjuvants and Other Types Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2014 through2021 and % CAGR
Table 37: USA 16-Year Perspective for Vaccine Adjuvants by Type -Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 38: USA Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 39: USA Historic Review for Vaccine Adjuvants by DiseaseType - Infectious Diseases, Cancer and Other Disease TypesMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2014 through 2021 and % CAGR
Table 40: USA 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 41: USA Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 42: USA Historic Review for Vaccine Adjuvants by Category -Human and Veterinary Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2014 through 2021 and % CAGR
Table 43: USA 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
CANADATable 44: Canada Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 45: Canada Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, PathogenComponents, Combination Adjuvants and Other Types Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2014 through 2021 and % CAGR
Table 46: Canada 16-Year Perspective for Vaccine Adjuvants byType - Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 47: Canada Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 48: Canada Historic Review for Vaccine Adjuvants byDisease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 49: Canada 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 50: Canada Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 51: Canada Historic Review for Vaccine Adjuvants byCategory - Human and Veterinary Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 52: Canada 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
JAPANVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Japan for 2023 (E)Table 53: Japan Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 54: Japan Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components,Combination Adjuvants and Other Types Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2014 through2021 and % CAGR
Table 55: Japan 16-Year Perspective for Vaccine Adjuvants byType - Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 56: Japan Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 57: Japan Historic Review for Vaccine Adjuvants byDisease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 58: Japan 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 59: Japan Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 60: Japan Historic Review for Vaccine Adjuvants byCategory - Human and Veterinary Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 61: Japan 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
CHINAVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in China for 2023 (E)Table 62: China Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 63: China Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components,Combination Adjuvants and Other Types Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2014 through2021 and % CAGR
Table 64: China 16-Year Perspective for Vaccine Adjuvants byType - Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 65: China Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 66: China Historic Review for Vaccine Adjuvants byDisease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 67: China 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 68: China Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 69: China Historic Review for Vaccine Adjuvants byCategory - Human and Veterinary Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 70: China 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
EUROPEVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Europe for 2023 (E)Table 71: Europe Recent Past, Current & Future Analysis forVaccine Adjuvants by Geographic Region - France, Germany,Italy, UK and Rest of Europe Markets - Independent Analysis ofAnnual Sales in US$ Thousand for Years 2022 through 2030 and %CAGR
Table 72: Europe Historic Review for Vaccine Adjuvants byGeographic Region - France, Germany, Italy, UK and Rest ofEurope Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 73: Europe 16-Year Perspective for Vaccine Adjuvants byGeographic Region - Percentage Breakdown of Value Sales forFrance, Germany, Italy, UK and Rest of Europe Markets for Years2014, 2023 & 2030
Table 74: Europe Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 75: Europe Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, PathogenComponents, Combination Adjuvants and Other Types Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2014 through 2021 and % CAGR
Table 76: Europe 16-Year Perspective for Vaccine Adjuvants byType - Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 77: Europe Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 78: Europe Historic Review for Vaccine Adjuvants byDisease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 79: Europe 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 80: Europe Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 81: Europe Historic Review for Vaccine Adjuvants byCategory - Human and Veterinary Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 82: Europe 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
FRANCEVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in France for 2023 (E)Table 83: France Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 84: France Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, PathogenComponents, Combination Adjuvants and Other Types Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2014 through 2021 and % CAGR
Table 85: France 16-Year Perspective for Vaccine Adjuvants byType - Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 86: France Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 87: France Historic Review for Vaccine Adjuvants byDisease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 88: France 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 89: France Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 90: France Historic Review for Vaccine Adjuvants byCategory - Human and Veterinary Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 91: France 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
GERMANYVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Germany for 2023 (E)Table 92: Germany Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 93: Germany Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, PathogenComponents, Combination Adjuvants and Other Types Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2014 through 2021 and % CAGR
Table 94: Germany 16-Year Perspective for Vaccine Adjuvants byType - Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 95: Germany Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 96: Germany Historic Review for Vaccine Adjuvants byDisease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 97: Germany 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 98: Germany Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 99: Germany Historic Review for Vaccine Adjuvants byCategory - Human and Veterinary Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 100: Germany 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
ITALYTable 101: Italy Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 102: Italy Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, PathogenComponents, Combination Adjuvants and Other Types Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2014 through 2021 and % CAGR
Table 103: Italy 16-Year Perspective for Vaccine Adjuvants byType - Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 104: Italy Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 105: Italy Historic Review for Vaccine Adjuvants byDisease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 106: Italy 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 107: Italy Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 108: Italy Historic Review for Vaccine Adjuvants byCategory - Human and Veterinary Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2014 through 2021 and% CAGR
Table 109: Italy 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
UNITED KINGDOMVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in the United Kingdom for 2023 (E)Table 110: UK Recent Past, Current & Future Analysis forVaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 111: UK Historic Review for Vaccine Adjuvants by Type -Particulate Adjuvants, Adjuvant Emulsions, Pathogen Components,Combination Adjuvants and Other Types Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2014 through2021 and % CAGR
Table 112: UK 16-Year Perspective for Vaccine Adjuvants by Type -Percentage Breakdown of Value Sales for ParticulateAdjuvants, Adjuvant Emulsions, Pathogen Components, CombinationAdjuvants and Other Types for the Years 2014, 2023 & 2030
Table 113: UK Recent Past, Current & Future Analysis forVaccine Adjuvants by Disease Type - Infectious Diseases, Cancerand Other Disease Types - Independent Analysis of Annual Salesin US$ Thousand for the Years 2022 through 2030 and % CAGR
Table 114: UK Historic Review for Vaccine Adjuvants by DiseaseType - Infectious Diseases, Cancer and Other Disease TypesMarkets - Independent Analysis of Annual Sales in US$ Thousandfor Years 2014 through 2021 and % CAGR
Table 115: UK 16-Year Perspective for Vaccine Adjuvants byDisease Type - Percentage Breakdown of Value Sales forInfectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 116: UK Recent Past, Current & Future Analysis forVaccine Adjuvants by Category - Human and Veterinary -Independent Analysis of Annual Sales in US$ Thousand for theYears 2022 through 2030 and % CAGR
Table 117: UK Historic Review for Vaccine Adjuvants by Category -Human and Veterinary Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2014 through 2021 and % CAGR
Table 118: UK 16-Year Perspective for Vaccine Adjuvants byCategory - Percentage Breakdown of Value Sales for Human andVeterinary for the Years 2014, 2023 & 2030
REST OF EUROPETable 119: Rest of Europe Recent Past, Current & FutureAnalysis for Vaccine Adjuvants by Type - Particulate Adjuvants,Adjuvant Emulsions, Pathogen Components, Combination Adjuvantsand Other Types - Independent Analysis of Annual Sales in US$Thousand for the Years 2022 through 2030 and % CAGR
Table 120: Rest of Europe Historic Review for Vaccine Adjuvantsby Type - Particulate Adjuvants, Adjuvant Emulsions, PathogenComponents, Combination Adjuvants and Other Types Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2014 through 2021 and % CAGR
Table 121: Rest of Europe 16-Year Perspective for VaccineAdjuvants by Type - Percentage Breakdown of Value Sales forParticulate Adjuvants, Adjuvant Emulsions, Pathogen Components,Combination Adjuvants and Other Types for the Years 2014, 2023 &2030
Table 122: Rest of Europe Recent Past, Current & FutureAnalysis for Vaccine Adjuvants by Disease Type - InfectiousDiseases, Cancer and Other Disease Types - Independent Analysisof Annual Sales in US$ Thousand for the Years 2022 through 2030and % CAGR
Table 123: Rest of Europe Historic Review for Vaccine Adjuvantsby Disease Type - Infectious Diseases, Cancer and Other DiseaseTypes Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2014 through 2021 and % CAGR
Table 124: Rest of Europe 16-Year Perspective for VaccineAdjuvants by Disease Type - Percentage Breakdown of Value Salesfor Infectious Diseases, Cancer and Other Disease Types for theYears 2014, 2023 & 2030
Table 125: Rest of Europe Recent Past, Current & FutureAnalysis for Vaccine Adjuvants by Category - Human andVeterinary - Independent Analysis of Annual Sales in US$Thousand for the Years 2022 through 2030 and % CAGR
Table 126: Rest of Europe Historic Review for Vaccine Adjuvantsby Category - Human and Veterinary Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2014 through2021 and % CAGR
Table 127: Rest of Europe 16-Year Perspective for VaccineAdjuvants by Category - Percentage Breakdown of Value Sales forHuman and Veterinary for the Years 2014, 2023 & 2030
ASIA-PACIFICVaccine Adjuvants Market Presence - Strong/Active/Niche/Trivial -Key Competitors in Asia-Pacific for 2023 (E)Table 128: Asia-Pacific Recent Past, Current & Future Analysisfor Vaccine Adjuvants by Type - Particulate Adjuvants, AdjuvantEmulsions, Pathogen Components, Combination Adjuvants and OtherTypes - Independent Analysis of Annual Sales in US$ Thousandfor the Years 2022 through 2030 and % CAGR
Table 129: Asia-Pacific Historic Review for Vaccine Adjuvantsby Type - Particulate Adjuvants, Adjuvant Emulsions, PathogenComponents, Combination Adjuvants and Other Types Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2014 through 2021 and % CAGR
Table 130: Asia-Pacific 16-Year Perspective for VaccineAdjuvants by Type - Percentage Breakdown of Value Sales forParticulate Adjuvants, Adjuvant Emulsions, Pathogen Components,Combination Adjuvants and Other Types for the Years 2014, 2023 &2030
Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.Reportlinker.Com/p06043964/?Utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Evolution Of Vaccine Adjuvants From Empirical Discovery To Rational Design
Vaccine adjuvants have evolved significantly since their inception, transitioning from empirical discovery to a more structured approach grounded in rational drug design. The origin of vaccine adjuvants dates back to early practices such as variolation, a method developed in the 16th century for inducing immunity against smallpox. Over time, the understanding and development of vaccines and adjuvants have greatly improved, leading to safer and more effective vaccines. This paper delves into the progression from empirical methods to the contemporary strategy of rational drug design, emphasizing the importance of understanding the structural and functional traits of adjuvants.
Rational adjuvant design: A new phaseTraditional adjuvant research relied on the empirical approach, with limited understanding of the mechanisms behind their immune-stimulatory effects. The introduction of rational design, based on detailed structural and functional knowledge of adjuvants and their corresponding receptors, marked a new era. Techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) provide the spatial interactions necessary to establish structure-activity relationships (SARs), paving the way for computer-aided design of superior adjuvants. A key focus is on saponin adjuvants, like those derived from Quillaja saponaria, which act on both innate and adaptive immune systems through specific functional groups and receptors. The identification of these receptors, potentially using bioorthogonal chemistry and proteomic methods, is crucial for advancing adjuvant design and understanding their mechanisms of action.
Synergism between immunology and medicinal chemistryThe discovery of adjuvants has historically been guided by antibody response evaluations in animals, which primarily measure humoral immunity. However, this approach falls short in assessing the full spectrum of adaptive immunity, including T-cell responses and cytokine profiles. Comprehensive immunological studies are essential to characterize the immune responses elicited by adjuvants accurately. Moreover, animal models may not always reflect human responses, necessitating careful consideration in study design. The complexity of adjuvant research is further compounded by the synergistic, antagonistic, or additive effects observed when combining different adjuvants, highlighting the need for a rational, structured approach in adjuvant design.
The role of saponins and their immunomodulatory propertiesSaponin adjuvants, particularly QS-21, have played a pivotal role in developing vaccines for diseases such as malaria and shingles. Despite their significance, the SARs and mechanisms of action (MOA) of saponin adjuvants remain inadequately understood, often due to incomplete immunological characterization. The structural complexity of saponins, coupled with their ability to modulate immune responses through mechanisms like T-cell co-stimulation and interaction with dendritic cells, underscores the need for a more rational and systematic approach to their study. Recent advances suggest that modifications to specific functional groups, such as the aldehyde and fucose residues, can drastically alter the immunological properties of saponins, making them key targets for further research.
Challenges and future directionsA significant challenge in adjuvant research is the misclassification of formulations as new adjuvants, leading to confusion and hindering progress in understanding their true immunological effects. The future of adjuvant research lies in the precise identification of cellular receptors for specific pharmacophores, particularly in complex adjuvants like saponins. Advanced techniques such as bioorthogonal chemistry, X-ray crystallography, and molecular modeling will be instrumental in this endeavor. The ultimate goal is to design novel adjuvants with enhanced safety and efficacy by leveraging a thorough understanding of their structural and functional characteristics.
ConclusionsThe shift from empirical to rational design in adjuvant research represents a significant advancement in vaccine development. By focusing on the molecular interactions between adjuvants and their cellular receptors, researchers can develop more effective immunomodulatory agents. This approach not only enhances vaccine efficacy but also holds potential for broader applications in treating autoimmune diseases and other conditions requiring precise immunological modulation. The continued integration of chemical proteomics, bioorthogonal chemistry, and systematic immunological studies will be crucial in realizing the full potential of vaccine adjuvants in modern medicine.
Source:
Journal reference:
Marciani, D. J. (2024). Vaccine Adjuvants: From Empirical to a More Rational Drug Design. Exploratory Research and Hypothesis in Medicine. Doi.Org/10.14218/erhm.2024.00002.
Vaccine Adjuvants Global Market Report 2023
ReportLinkerMajor players in the vaccine adjuvants market are GlaxoSmithKline Plc, Novavax, Inc, SPI Pharma, Agenus, Inc, CSL Limited, InvivoGen, Brenntag Biosector A/S, Adjuvatis, Merck KGaA, Croda International Plc, Seppic Inc, OZ Biosciences, Avanti Polar Lipids, Inc, Astellas Pharma Inc, Virometix AG, MPV Technologies Limited, and Adjuvance Technologies Inc.
New York, June 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.Com announces the release of the report "Vaccine Adjuvants Global Market Report 2023" - https://www.Reportlinker.Com/p06466615/?Utm_source=GNW
The global vaccine adjuvants market is expected to grow from $1.63 billion in 2022 to $1.77 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The vaccine adjuvants market is expected to reach $2.38 billion in 2027 at a CAGR of 7.7%.
The vaccine adjuvants market consists of sales of adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and saponin-based adjuvants.Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.
The value of goods in this market includes related services sold by the creators of the goods.
Vaccine adjuvants are compounds or ingredients used in vaccines that enhance the body's immunogenic response to antigens that lack immunostimulatory capabilities and help to create a stronger immune response.
North America was the largest region in the vaccine adjuvants market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in the vaccine adjuvants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main types of products of vaccine adjuvants are adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others such as saponin-based adjuvants.An adjuvant emulsion is a mixture of two or more ordinarily immiscible liquids.
The route of application includes human vaccine adjuvants and veterinary vaccine adjuvants administered through oral, intramuscular, intranasal, subcutaneous, and intradermal routes to treat cancer, infectious diseases, and other diseases including zoonotic diseases.
The rising prevalence of infectious diseases is expected to propel the growth of the vaccine adjuvants market going forward.Infectious diseases refer to infections caused by viruses, bacteria, fungi, or parasites.
Vaccines are used to treat these infectious diseases such as hepatitis B (HBV), hepatitis C (HCV), HIV, malaria, syphilis, and brucellosis. For instance, according to the 2022 World Health Organization (WHO) report, an estimated 10.6 million people are infected with tuberculosis globally in 2021, 1.6 million died, and 1.5 million people acquired HIV in 2021 while 650,000 people lost their lives due to it. Therefore, the rising prevalence of infectious diseases will drive the vaccine adjuvants market.
Strategic partnership is a key trend gaining popularity in the vaccine adjuvants market.Many companies operating in the vaccine adjuvants market are looking for partnerships to strengthen their position in the market.
For instance, in October 2021, Dynavax Technologies, a US-based biotech company partnered with the U.S. Department of Defense to develop an adjuvanted plague vaccine using Dynavax's CpG 1018 adjuvant. Furthermore, in September 2020, Valneva SE, a France-based biotech company, partnered with Dynavax, a US-based biotech company to produce an adjuvant for the COVID-19 vaccine.
In August 2022, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired Affinivax Inc. For a deal amount of $3.3 billion. The acquisition of Affinivax strengthens GSK's strategy to build a substantial portfolio of specialized novel drugs and vaccines. It comprises a next-generation 24-valent pneumococcal vaccine adjuvant (AFX3772), which is based on the incredibly ground-breaking Multiple Antigen Presenting System (MAPSTM) platform technology and is currently in phase II development. Affinivax Inc. Is a UK-based clinical-stage biopharmaceutical company operating in the vaccine adjuvant market.
The countries covered in the vaccine adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The vaccine adjuvants market research report is one of a series of new reports that provides vaccine adjuvants market statistics, including the vaccine adjuvants industry's global market size, regional shares, competitors with a vaccine adjuvants market share, detailed vaccine adjuvants market segments, market trends, and opportunities, and any further data you may need to thrive in the vaccine adjuvants industry. This vaccine adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.Read the full report: https://www.Reportlinker.Com/p06466615/?Utm_source=GNW
About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Comments
Post a Comment